InterMune wins FDA OK for lung-scarring disease drug at center of Roche deal
October 15, 2014 at 16:21 PM EDT
A treatment for a fatal lung-scarring disease — the center of an $8.3 billion buyout of a Peninsula company by drug giant Roche — won regulatory approval Wednesday...
